- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.06. | Steering generative AI into the pharma fast lane | ||
| 29.06. | Oxford BioTherapeutics announces clinical milestones from its collaboration with Boehringer Ingelheim | ||
| 26.06. | Pfizer announces phase 3 results for potential non-small cell lung cancer treatment | ||
| 26.06. | MRM Health appoints Hans-Jürgen Wörle as Independent Director | ||
| 25.06. | MRM Health appoints Michel Detheux as Chairman of the Board | ||
| 25.06. | Gilead's Trodelvy approved by EC as first-line treatment for metastatic triple-negative breast cancer | ||
| 24.06. | Sanofi's Cenrifki approved in Europe for secondary progressive MS without relapses | ||
| 24.06. | Lundbeck appoints Tarek Samad as EVP, Head of Research & Development | ||
| 23.06. | AbbVie to acquire Apogee Therapeutics in $10.9bn deal | ||
| 23.06. | Biogen to acquire RayThera in $1bn deal | ||
| 22.06. | Regeneron's New Drug Application for cemdisiran accepted for review by FDA and EMA | ||
| 22.06. | Sanofi appoints Paulo Fontoura as Global Head of R&D | ||
| 18.06. | Sanofi's Sarclisa approved by MHRA as UK's first anti-cancer treatment given via on-body injector | ||
| 18.06. | Pfizer appoints Cecile Guegan as Interim CFO | ||
| 17.06. | Takeda's new study data for oveporexton shows improvements in narcolepsy type 1 | ||
| 17.06. | Broken String Biosciences appoints Bruce Eaton as Chairman of the Board | ||
| 16.06. | Bridging the gap between European brain innovation and real-world policy | ||
| 16.06. | Gilead's New Drug Application for Yeztugo accepted by US FDA | ||
| 15.06. | Ultomiris gets US FDA Priority Review for immunoglobulin A nephropathy treatment | ||
| 15.06. | Fondazione Telethon appoints Graciana Diez-Roux as new Scientific Director | ||
| 12.06. | Novo Nordisk's Wegovy approved as UK's first daily GLP-1 weight loss pill | ||
| 12.06. | Obesity care in the UK - why it can't improve until it is recognised as a disease | ||
| 11.06. | Roche's Tecentriq gets FDA Priority Review for specific stage 3 colon cancer | ||
| 11.06. | Oriva Therapeutics appoints Agnès Arbat as CEO | ||
| 10.06. | Lilly's Ebglyss approved by FDA as maintenance dose for atopic dermatitis |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.